Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Tumor-informed molecular residual disease assays

In one sentence

A tumor-informed molecular residual disease assay uses features identified in a tumor sample to look for a qualifying tumor signal in later blood samples.

The intuition

A familiar handwriting sample can help you look for the same writer in a pile of scraps. You are asking whether recognizable features appear, rather than reading every possible message.

A tumor-informed assay starts with a tumor reference. It then tracks selected features in blood. The handwriting analogy is limited: sequence errors and other biological sources can imitate a feature, so origin and error controls are part of the method.

How it works

First, a laboratory profiles tumor material and, under its method, suitable non-tumor material. It selects a set of features for a personalized assay. For mutation-based designs, these are chosen tumor-associated sequence changes. The exact selection method and number of targets vary.

Next, blood is collected and its cell-free DNA (cfDNA) is extracted. The test looks for evidence at the selected targets. Multiple reads of the same original molecule are not multiple independent molecules. Error suppression and the rule for combining evidence across targets matter.

The later blood test looks for circulating tumor DNA (ctDNA). The assay reports whether its qualifying molecular residual disease (MRD) signal was detected. It may also report an assay-specific quantity. MRD refers to the molecular finding in a treatment context; a positive assay does not by itself establish that disease is below imaging resolution.

A fixed target list also creates a boundary. The test may track known variants well while missing a new alteration outside the list. It cannot be assumed to discover every resistance mechanism. Rebuilding a panel and broad genomic profiling are different tasks.

Why it matters in cancer

A reference can help distinguish low tumor signal from background. It also creates dependencies: suitable tissue, successful assay construction, relevant targets and enough tumor DNA in the blood sample. The right question is whether a particular assay has evidence for its proposed use.

How it is measured

Assay-card fieldWhat to inspect
MeasuresEvidence for selected tumor-associated features in blood
HowProfile reference material, select features, extract plasma DNA, test targets, apply a result rule
Input and tissue costReference tumor material plus required normal material; later blood draws; tissue requirements vary
Output and unitsDetection call and any calibrated quantity, with version-specific definitions
ThresholdsQualifying-target and signal rules established by the method's validation
Failure modesBuild failure, low shedding, inadequate input, target loss, contamination or mistaken origin
What it cannot tell youLesion location, every new mutation, zero disease after a negative draw, or which treatment helps
Validation and intended useCheck the specific assay, jurisdiction, disease setting and proposed decision

Common confusions

Tumor-informed versus always more sensitive: a design category does not establish a universal ranking. Compare assays under compatible inputs and clinical settings.

Tumor-naive versus mutation discovery: an assay without a tissue reference may detect a cancer-associated pattern without supplying a broad mutation profile.

Reference tumor versus current tumor: evolution and sampling differences can change which features remain informative.

Predicting recurrence versus improving outcomes: risk association and benefit from an assay-guided intervention require different evidence.

ctDNA units and limits, prognostic versus predictive biomarkers, and validity and utility.

Sources and scope

Source check: October 9, 2026. This describes an assay category; product indications and care decisions require current, setting-specific review. Expert and learner review pending.

Used in